AstraZeneca settles drug-pricing suit for $103M

AstraZeneca (NYSE: AZN) says it will pay $103 million to settle a class-action suit in the U.S. over its pricing for wholesale drugs, even though it believes its pricing and marketing practices were lawful. Report